Oral
valacyclovir is better absorbed than oral
acyclovir, increasing
acyclovir bioavailability three- to fivefold. This provides the opportunity to explore whether high systemic
acyclovir concentrations are effective in the treatment of
cold sores (
herpes labialis). Two randomized, double-blind, placebo-controlled studies were conducted. Subjects were provided with 2 g of
valacyclovir twice daily for 1 day (1-day treatment), 2 g of
valacyclovir twice daily for 1 day and then 1 g of
valacyclovir twice daily for 1 day (2-day treatment), or a matching placebo and instructed to initiate treatment upon the first symptoms of a
cold sore. In study 1, the median duration of the episode (primary endpoint) was reduced by 1.0 day (P = 0.001) with 1-day treatment and 0.5 days (P = 0.009) with 2-day treatment compared to placebo. Similarly, the mean duration of the episode was statistically significantly reduced by 1.1 days with 1-day treatment and 0.7 days with 2-day treatment compared to placebo. The proportion of subjects in whom
cold sore lesion development was prevented and/or blocked was increased by 6.4% (P = 0.096) with 1-day treatment and 8.5% (P = 0.061) with 2-day treatment compared to placebo. The time to lesion healing and time to cessation of
pain and/or discomfort were statistically significantly reduced with
valacyclovir compared to placebo. In study 2, results similar to those in study 1 were obtained. AEs were similar across treatment groups. These studies provide evidence supporting a simple, 1-day
valacyclovir treatment regimen for
cold sores that is safe and effective. The 1-day
valacyclovir regimen offers patients a unique and convenient dosing alternative compared to available topical
therapies.